Figure S1 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer

Key Points

Combination therapy significantly improves treatment efficacy in pancreatic cancer.
MTAP-deletion status influences the effectiveness of PRMT5 inhibitors in cancer treatment.
Cell cycle analysis reveals critical insights into the effects of PRMT5 inhibition.
The study highlights a potential strategy for targeting KRAS-mutant cancers.
simple_explanation: MTAP-deleted pancreatic cancer cells respond better to a mix of PRMT5 and KRAS inhibitors. The treatment shows promising results in slowing down cell growth and affecting the cell cycle. This approach could change how we treat certain aggressive pancreatic cancers, offering hope for improved patient outcomes.

Combination of PRMT5 inhibitors and KRAS inhibitors improves outcomes in MTAP-deleted pancreatic cancer, suggesting new therapeutic strategies.

Figure S1 shows MTAP-deletion status of PDAC cell lines and cell cycle analysis of PRMT5i-treated cells.

No takes yet. Share an insight, caveat, or question.

Drizyte‐Miller et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share